Coherus Oncology (FRA:8C5) Moat Score: 4/10 (As of Jul. 08, 2026)


FRA:8C5 Coherus Oncology Inc FRA:8C5
45 GF Score
Price €1.34
GF Value €0.62
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Coherus Oncology Moat Score?

Coherus Oncology FRA:8C5 +6.53% 45 Moat Score is 4 as of Jul. 08, 2026. GuruFocus rates FRA:8C5 with a GF Score™ of 45/100 and a GF Value™ of €0.62 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,394 Biotechnology companies, Coherus Oncology ranks better than 88.74% on this metric.

Coherus Oncology has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Coherus Oncology has Narrow Moat: Coherus Oncology Inc has a discernible moat due to its valuable intellectual property and patents in oncology treatments. However, the biotech industry is highly competitive, and its market share is not dominant.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Coherus Oncology might have Narrow Moat - Discernible but modest moat.

Coherus Oncology  (FRA:8C5) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Coherus Oncology Moat Score Related Terms

FRA:8C5 vs TARA, KPTI, CNTN: Moat Score Comparison

For the Biotechnology subindustry, Coherus Oncology's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus Oncology Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's Moat Score distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's Moat Score falls into.


FRA:8C5
45GF Score
Coherus Oncology Inc FRA:8C5
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Coherus Oncology (FRA:8C5) has a Moat Score of 4 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Coherus Oncology ranks #157 out of 1394 companies in the Biotechnology industry, placing it in the top 11.3%.
Is Coherus Oncology's Moat Score too high?
Coherus Oncology's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Coherus Oncology's value of 4 is 100% above this industry median. Based on the distribution chart, Coherus Oncology ranks #157 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Coherus Oncology has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Moat Score compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #157 out of 1394 companies for Moat Score. This places Coherus Oncology in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Coherus Oncology's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.62, compared to a current price of €1.34 — trading 115.8% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Coherus Oncology's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Moat Score is 4 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.34 is trading 115.8% above its estimated GF Value™ of €0.62. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for FRA:8C5:

  • Moat Score: 4
  • GF Value™: €0.62 vs. price of €1.34 (115.8% above fair value)
  • GF Score™: 45/100 with 6 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1394)

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges CHRS:USA
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
45GF Score

Get the complete analysis for FRA:8C5

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.34
Price
€0.62
GF Value